Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today ...
CE-IVD certification puts Ella in focus for Bio-Techne investors Bio-Techne (TECH) just secured CE-IVD marking for its Ella benchtop immunoassay platform in the European Union, opening the door for ...
StockStory.org on MSN
Bio-Techne (NASDAQ:TECH) surprises with Q4 CY2025 sales
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results , but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ ...
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...
Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.
MINNEAPOLIS, Feb. 2, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the launch of Cultrex™ ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity market ...
ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an ...
Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...
RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...
The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...
Bio-Techne's Ella platform achieves CE-IVD marking expanding access to rapid, cartridge-based immunoassays for European clinical labs: Minneapolis Tuesday, February 17, 2026, 14:0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results